Vaccines
Gary Grohmann A B and Robert Booy B CA
B
C
Gary Grohmann BSc(Hons) PhD FASM (right) is a consultant virologist and a Director of Environmental Pathogens P/L, as well as a Board Member, and member of the Scientific Advisory Committee, of the Immunisation Coalition. He is an Adjunct Professor in Infectious Diseases and Immunology at The University of Sydney. He was Head of Immunobiology at the Therapeutic Goods Administration for 17 years and then a consultant to the World Health Organization on influenza and COVID‐19 matters for 7 years. |
|
Robert Booy MBBS, MSc, MD, FRACP, FRCPCH (left) is a Senior Professorial Fellow, Children’s Hospital at Westmead School of Child and Adolescent Health, University of Sydney. He has over 300 publications and has supervised 30 doctoral students. Robert has a long-term interest in the control and prevention of serious infectious diseases. He was a Board Member of the Immunisation Coalition for 12 years and still serves on its Scientific Advisory Committee as Chair. |
Gary Grohmann BSc(Hons) PhD FASM (right) is a consultant virologist and a Director of Environmental Pathogens P/L, as well as a Board Member, and member of the Scientific Advisory Committee, of the Immunisation Coalition. He is an Adjunct Professor in Infectious Diseases and Immunology at The University of Sydney. He was Head of Immunobiology at the Therapeutic Goods Administration for 17 years and then a consultant to the World Health Organization on influenza and COVID‐19 matters for 7 years. |
Robert Booy MBBS, MSc, MD, FRACP, FRCPCH (left) is a Senior Professorial Fellow, Children’s Hospital at Westmead School of Child and Adolescent Health, University of Sydney. He has over 300 publications and has supervised 30 doctoral students. Robert has a long-term interest in the control and prevention of serious infectious diseases. He was a Board Member of the Immunisation Coalition for 12 years and still serves on its Scientific Advisory Committee as Chair. |
References
1 Immunisation Coalition (2023) Annual Report 2023. https://immunisationcoalition.org.au/wp-content/uploads/2024/04/Annual-Report-2023.pdf
2 Sanae A et al. (2022) Vaccine value chain: an overview and challenges, In ‘2022 14th International Colloquium of Logistics and Supply Chain Management (LOGISTIQUA)’, 25–27 May 2022, El Jadida, Morocco. pp. 1–6. IEEE. doi:10.1109/LOGISTIQUA55056.2022.9938030
3 Hall J et al. (2024) Australia’s Vaccine Chain Value Conference. Biointellect. https://www.biointelect.com/wp-content/uploads/2024/08/AVVCC24-Outputs-Final-launch-08082024.pdf
4 Woodward M (2024) Enhancing longevity: the additional benefits of vaccination in older adults. Microbiol Aust 45(4), 175-178.
| Crossref | Google Scholar |
5 Jayasinghe S (2024) Pneumococcal conjugate vaccines in children. Microbiol Aust 45(4), 179-183.
| Crossref | Google Scholar |
6 Flanagan KL, Wood JG (2024) Unlocking the value of Shingrix: how vaccination empowers older adults. Microbiol Aust 45(4), 184-187.
| Crossref | Google Scholar |
7 Barr G (2024) Influenza in Australia before, during and after the COVID-19 pandemic. Microbiol Aust 45(4), 188-192.
| Crossref | Google Scholar |
8 Liu B (2024) COVID-19 vaccine effectiveness monitoring in Australia. Microbiol Aust 45(4), 193-195.
| Crossref | Google Scholar |
9 Buttery JP et al. (2024) SnotWatch: data collaboration informing disease impact. Microbiol Aust 45(4), 196-200.
| Crossref | Google Scholar |
10 Hart B (2024) The evolving role of Australian community pharmacists in vaccination: challenges and opportunities. Microbiol Aust 45(4), 201-204.
| Crossref | Google Scholar |
11 Cheng C (2024) Respiratory virus surveillance in Australia: past, present and future. Microbiol Aust 45(4), 205-207.
| Crossref | Google Scholar |
12 Perlman S (2024) Recent pandemics and informed predictions. Microbiol Aust 45(4), 208-210.
| Crossref | Google Scholar |
